AstraZeneca PLC Responds to U.S. Regulator Decision on Blood-Thinner Brilinta

Bloomberg -- AstraZeneca Plc told the U.S. Food and Drug Administration that high-dose aspirin most likely caused different results in a test of the Brilinta blood thinner, citing an analysis requested by the regulator.